The shares of MINDBODY, Inc. (NASDAQ:MB) has been pegged with a rating of Mkt Perform by JMP Securities in its latest research note that was published on January 24th, 2019. JMP Securities wasn’t the only research firm that published a report of MINDBODY, Inc., with other equities research analysts also giving their opinion on the stock. Jefferies advised investors in its research note published on January 9th, 2019, to Hold the MB stock. The stock had earned Outperform rating from Imperial Capital when it published its report on November 8th, 2018. That day the Imperial Capital set price target on the stock to $36. The stock was given Neutral rating by ROTH Capital in its report released on November 7th, 2018. JP Morgan was of a view that MB is Neutral in its latest report on November 7th, 2018. William Blair thinks that MB is worth Mkt Perform rating. This was contained in the firm’s report on September 26th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 9 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $36.50. The price of the stock the last time has raised by 68.95% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 69.42.
The shares of the company dipped by -0.05% during the trading session on Friday, reaching a low of $36.41 while ending the day at $36.51. During the trading session, a total of 2.35 million shares were traded which represents a -44.18% decline from the average session volume which is 1.63M shares. MB had ended its last session trading at 36.53. MINDBODY, Inc. currently has a market cap of $1.66B while its P/E earnings growth sits at 7.26, with a beta of -0.35. MINDBODY, Inc. debt-to-equity ratio currently stands at 0.89, while its quick ratio hovers at 9.40. MB 52-week low price stands at $21.61 while its 52-week high price is $45.50.
The company in its last quarterly report recorded -$0.05 earnings per share which is above the -$0.07 predicted by most analysts. The MINDBODY, Inc. generated $63.78 million in revenue during the last quarter, which is slightly lower than the $63.97 million predicted by analysts. In the second quarter last year, the firm recorded -$0.06 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -20%. MINDBODY, Inc. has the potential to record -0.79 EPS for the current fiscal year, according to equities analysts.
Investment analysts at B. Riley FBR published a research note on September 7th, 2018 where it informed investors and clients that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now rated as Buy. Their price target on the stock stands at $19. Jefferies also rated ARWR as Downgrade on January 9th, 2019, with its price target of $380 suggesting that ARWR could surge by 32.79% from its current share price. Even though the stock has been trading at $13.30/share, analysts expect it to surge higher by 17.74% to reach $23.30/share. It started the day trading at $15.78 and traded between $12.72 and $15.66 throughout the trading session.
A look at its technical shows that ARWR’s 50-day SMA is 13.70 while its 200-day SMA stands at 13.76. The company’s average trading volume currently stands at 1.64M shares, which means that the short-interest ratio is just 10.63 days. Over the past seven days, the company moved, with its shift of 9.51%. Looking further, the stock has raised 5.88% over the past 90 days while it lost -2.85% over the last six months.
RTW Investments LP meanwhile sold more ARWR shares in the recently filed quarter, changing its stake to $94,444,475 worth of shares. BlackRock Fund Advisors followed the path by decreasing its ARWR portfolio by -0.34% in the quarter. This means that BlackRock Fund Advisors sold -22,103 shares in the last quarter and now controls 6,569,287 shares of the ARWR stock, with the valuation hitting $81,590,545.
Similarly, SSgA Funds Management Inc increased its Arrowhead Pharmaceuticals, Inc. shares by +22.39% during the recently filed quarter. After buying 902,897 shares in the last quarter, the firm now controls 4,934,753 shares of Arrowhead Pharmaceuticals, Inc. which are valued at $61,289,632. In the same vein, The Vanguard Group Inc increased its Arrowhead Pharmaceuticals, Inc. shares by during the most recent reported quarter. The firm bought 8,888 shares during the quarter which increased its stakes to 3,772,611 shares and is now valued at $46,855,829. Following these latest developments, around 4.60% of Arrowhead Pharmaceuticals, Inc. stocks are owned by institutional investors and hedge funds.